Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theravance Biopharma, Inc.TBPH · Entity 5037 | Sr. VP, Technical Operations | February 20, 2017 | February 23, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theravance Biopharma, Inc.
Report date February 20, 2017 · Filed February 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 225,071 |
Reported balance
After 2017-02-20 transaction · row 1
1 source rowRow 1 · 2017-02-20 · Tax withholding · Disposed 9,611 · Balance 225,071 |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 9,000 |
Reported balance
Holding disclosure · report date 2017-02-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,000 F1: By Spouse as holder of self directed retirement account. Reporting person disclaims beneficial ownership of these securities in excess of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: By Spouse as holder of self directed retirement account. Reporting person disclaims beneficial ownership of these securities in excess of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2017 Filed Feb 23, 2017 00:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 9,611 | $33.78 | $324,659.58 |
DisclosureSEC source: 0001179110-17-002991 · edgar.xml · nonDerivative · entry 1 LEE JUNNING · CIK 0001596187 · Sr. VP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,071 Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 23:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,785 | $31.96 | $120,968.60 |
DisclosureSEC source: 0001179110-16-031978 · edgar.xml · nonDerivative · entry 1 LEE JUNNING · CIK 0001596187 · Sr. VP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,682 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.